Investors are rushing into the relative safe haven of the bond market, causing the yield on the U.S. 10-year Treasury to plummet.Real Estateread more
President Donald Trump on Thursday directed the U.S. intelligence community to "quickly and fully cooperate" with Attorney General William Barr's investigation into the...Politicsread more
The U.S. Commerce Department said its proposed rule would amend the normal countervailing duty process to include new criteria for currency undervaluation.World Economyread more
Asia Pacific markets traded mixed on Friday morning as investors remained worried over trade tensions between the United States and China.Asia Marketsread more
Wall Street is becoming convinced that both the White House and Beijing are willing to engage in a protracted trade war that could begin to hit consumers and slow global...Market Insiderread more
Stocks fell sharply on Thursday as investors started to fear the U.S.-China trade war is slowing the economy.Marketsread more
"The last thing I want is to put a date out there for lifting the grounding," said Dan Elwell, acting administrator for the FAA.Transportationread more
The charges allege he published secret documents obtained by former Army intelligence analyst Chelsea Manning, some of which included the disclosure of foreigners who were...Politicsread more
TransferWise, the money transfer start-up, was valued at $3.5 billion after investors bought $292 million of shares in a secondary sale.Technologyread more
See which stocks are posting big moves after the bell on Thursday, May 23.Market Insiderread more
Sentiment is "not negative enough to trigger a huge rally ... unless we get some kind of real breakthrough with China," Jim Cramer says.Mad Money with Jim Cramerread more
The pharmaceutical industry has donated $589,344 to Hillary Clinton's campaign, according to the nonprofit research group Center for Responsive Politics. That's more than any other candidate — despite Clinton's proclamation that she's proud to call the pharmaceutical industry her enemy.
"Price gouging like this in the specialty market is outrageous," Clinton tweeted in September, referring to the now-infamous decision by Turing Pharmaceuticals to raise the price of a decades-old medicine by 5,000 percent overnight. "Tomorrow I'll lay out a plan to take it on."
That was Sept. 21. The IBB, an exchange-traded fund that tracks the biotech industry, promptly sank almost 5 percent. Through this week, it has lost almost 30 percent.
Clinton hasn't let up on drugmakers. Last week, she released a campaign ad directly targeting Valeant Pharmaceuticals, another pharmaceutical company in the crosshairs for hiking prices of old medicines (though Valeant has since run into other troubles).
The contributions in support of Clinton come mainly from individual donors who work for pharmaceutical companies, according to the Center for Responsive Politics. They may also include contributions from political action committees associated with drug companies.
And despite Clinton's antipharma rhetoric, some say she may actually be the industry's safest choice.
"Hillary would probably be positive at this point because at least her policies are identifiable, understandable and likely to get toned down somewhat," said Brian Skorney, an analyst with Robert W. Baird.
Both Bernie Sanders and Donald Trump, Skorney said, would be the most negative, "both because they will utilize rhetoric to attack the industry and make an effort to enact extreme changes that they can't possibly predict the ramifications of."
It's worth noting that Clinton has received the most contributions overall — not just from the pharmaceutical industry. But the drugmakers she's declared as her enemy don't appear to feel the same way.